Plasmatic cytokine network in patients with laryngeal carcinoma after surgical treatment

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3621-3625

  Pignataro, Lorenzo ^a   Corsi, Massimiliano M ^a   Sambataro, Giuseppe ^a   Porcaro, Luigi ^a   Tredici, Paola ^a   Broich, Guido ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Blood; Elisa; Interleukin 10; Interleukin 12; Interleukin 6; Laryngeal carcinoma

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; IMMUNOREGULATION; INFLAMMATION; LARYNX CARCINOMA; MALE; METABOLISM; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; INTERLEUKINS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED;

EID: 0035568896     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: Correlations with extent of tumor and prognosis
2. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony stimulating factor and contained CD34+ natural suppressor cells
3. Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carcinoma: A clinical-pathologic correlation
4. Mechanisms of immune suppression in patients with head and neck cancer: Presence of CD34+ cells with suppressed immune functions within cancers that secrete granulocytemacrophage colony-stimulating factor
5. Inhibition of interleukin-8 attenuates angiogenesis in bronchogenic carcinoma
6. Cancer cachexia
7. Antigen-presenting function of the macrophage
8. IL-12: A key cytokine in immune regulation
9. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of head and neck
10. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients
11. T cell deficiency in patients with squamous cell carcinoma of the head and neck
12. Immunological evaluation and prognosis in patients with head and neck cancer
13. Cellular immunity in patients with epidermoid carcinoma of the head and neck
14. Natural killer cell activity and head and neck cancer: Clinical assessment
15. NK cell activity in patients with carcinoma of the larynx and hypopharynx
16. Inhibition of LAK generation by blocking factors in sera of patients with head and neck carcinoma
17. Influence of serum derived from patients with head and neck cancer on natural killer cell activity
18. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer
19. Two types of mouse T helper cells. Th 2 clones secrete a factor that inhibits cytokine production by Th1 clones
20. Interleukin-10 (IL-10) inhibits cytokines synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
21. IL-10 inhibits human T cell proliferation and IL-2 production
22. Physiopathology of IL-12 in human solid neoplasms: Blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy
23. Relationship between serum levels of interleukin-6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma
24. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer
25. Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis
26. Constitutive production of interleukin-6 by ovarian cancer cell lines and by primary ovarian tumor cultures
27. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma
28. Production by human squamous cell carcinoma of a factor inducing activation and proliferation of immune cells
29. Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer
30. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes
31. Induction by cytokine administration in humans
32. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer
33. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck
34. Interleukin-10
35. Interleukin-12: A new clinical player in cytokine therapy
36. Interleukin-12 in early or advanced cancer patients